Investor Relations - OxySure Therapeutics, Inc. (OTCQB: OXYS)

OxySure Therapeutics, Inc. (formerly, OxySure Systems, Inc., 'OXYS') is the world leader in short duration/emergency duration medical oxygen and respiratory solutions for mass market use. Based in Texas, USA the company develops, manufactures and sells a safe and easy to use solution to produce medically pure oxygen from two dry inert, proprietary powders. OxySure has numerous patents issued and pending on this proprietary process and methodology that is revolutionizing the emergency short duration oxygen supply marketplace. With this technology, oxygen is generated on demand. There is no storage of oxygen. There are no compressed tanks, no dials, no valves, no regulatory maintenance, no hydrostatic testing, no batteries, no required training, and none of the hazards associated with traditional oxygen provision systems. OxySure makes the delivery devices lighter, safer, more affordable and easier to use.

OxySure improves access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health” (IDLH) environments. In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and Heartsine), QuikClot Bleeding Control solutions, resuscitation products and pulse oximetry products.

The OxySure Model 615 is the world's first portable emergency oxygen device for mass lay person use. FDA cleared for over the counter sale, it allows any lay person - a bystander, colleague or loved one - to administer medical oxygen during those first critical minutes after a medical emergency occurs, while waiting for first responders to arrive. The product is also CE Marking approved, and has been used in thousands of saves.

 

Hot off the press

Monday April 18, 2016: OxySure issues clarification: "The Company is continuing its previously stated operational strategy, which includes a generation 2 product, and evaluating an outsourcing strategy. At the same time, the Company is pursuing multiple strategic options, including the continuation of its efforts to pursue its previously stated goal of evaluating inorganic growth options."  

 

Investor Highlights

               Fourteen (14) consecutive quarters of revenue growth (5 quarters at triple digit growth; 8 quarters at double digit growth)

               TTM Revenue $3.4 million; Revenue run rate ~ $5 million; Margins 56% - 62%; Ave. annual growth rate over 3 years 216%; Ave. quarterly growth rate over 14 quarters 243%

               Patented technology
               Recurring revenue model
               First mover advantage
               Enormous end user markets
               FDA cleared (OTC); CE Marking approved
               Additional vertical markets

OxySure in the News

OXYS Stock Alert

  

Matt Lauer, Today Show Interviews Kylee Shea and Family

Video News Clip on WFAA News Channel 8

OXYS Stock Alert

 

OxySure Obtains CE Marking Approval

 

Stonegate Securities Initiates Coverage on OxySure Systems

OXYS Corporate Update Featured on InvestmentPitch.com

OXYS Corporate Update Featured on InvestmentPitch.com 

 

Taglich Brothers Initiates OXYS With Price target of $2.10

InvestmentPitch Media Reports on OXYS 3Q15 Financial Results

 

Recent Analyst Reports

 

 

See all analyst reports

 

Investor Events

Shareholder Update Call March 17, 2016 

Audio File of Shareholder Update Call

OxySure (OXYS) 3Q 2015 Earnings Call November 16, 2015 

Earnings Presentation (PDF), Earnings Press Release

OxySure (OXYS) 2Q 2015 Earnings Call August 19, 2015

Earnings Presentation (PDF), Earnings Press Release

OxySure (OXYS) 1Q15 Earnings Call May 19, 2015 

Earnings Presentation (PDF), Earnings Press Release 

OxySure (OXYS) 4Q FY2014 Earnings Call March 31, 2015

Earnings Presentation (PDF)Earnings Press Release, Audio File

OxySure (OXYS) 3Q14 Earnings Call November 14, 2014

 Earnings Presentation (PDF)Earnings Press Release

Investor Call to Discuss Merger with Estill Medical October 23, 2014

Presentation (PDF)

OxySure (OXYS) 2Q 2014 Earnings Call August 15, 2014

Earnings Presentation (PDF), Earnings Press Release

OxySure (OXYS) 1Q 2014 Earnings Call May 16, 2014 Earnings Presentation (PDF), Earnings Presentation (Flipbook),  Earnings Press Release

OxySure (OXYS) FY 2013 Earnings Call April 16, 2014

Earnings Presentation (PDF), Earnings Press Release

OxySure (OXYS) Investor Update Conference Call, February 4, 2014

Presentation (PDF)
OxySure (OXYS) 3Q13 Financial Results, November 14, 2013 Earnings Presentation, Earnings Press Release, PDF

OxySure (OXYS) 2Q13 Earnings Call, August 13, 2013

Presentation, Audio, PDF
OxySure (OXYS) Building Momentum in 2013 - Zacks Zacks Report
OxySure CEO audio interview on Quality Stocks.com Audio File
FY2012 Financial Results and Update Conference Call Audio FilePress Release
Company Fact Sheet May 2013 Company Fact Sheet

OxySure (OXYS) - Taglich Brothers Investment Report

Investment Report

 

 

Recent SEC Filings

FORM TYPE

DATE FILED

PERIOD ENDING

DOCUMENTS

8-K 2016-04-12 April 12, 2016

8-K, Exhibits 3.1, 3.2

10-K 2016-03-30 December 31, 2015

10-K

5/A  2016-03-07 December 31, 2015

5/A

5/A 2016-03-03 December 31, 2015

5/A

PRE 14A 2016-02-26 February 26, 2016

PRE 14A

5 2016-02-16 December 31, 2015

5

5 2016-02-16 December 31, 2015

5

5 2016-02-16 December 31, 2015

5

8-K 2016-01-28 January 28, 2016

8-K, Exhibit 99.1

SC 13G 2015-12-11 December 4, 2015

SC 13G

SC 13G 2015-12-11 December 1, 2015

SC 13G

4 2015-12-09 December 4, 2015

4

8-K 2015-12-02 December 2, 2015

8-K, Exhibits 3.1, 99.1

10-Q 2015-11-16 September 30, 2015

10-Q, Exhibits 31.1, 31.2, 32

XBRL File (Zip Format)

8-K 2015-11-09 November 9, 2015 8-K, Exhibit 99.1
4 2015-11-09 September 14, 2015 4
4 2015-11-09 November 4, 2015 4
8-K 2015-11-09 November 9, 2015 8-K, Exhibit 99.1
8-K 2015-09-17 September 15, 2015 8-K
10-Q 2015-08-19 June 30, 2015 10-Q, Exhibits 31.1, 31.2, 32
DEF 14A 2015-08-18 August 18, 2015 DEF 14A
NT 10-Q 2015-08-17 June 30, 2015 NT 10-Q
4 2015-08-14 August 04, 2015 4
4 2015-08-14 August 12, 2015 4
3 2015-08-14 August 12, 2015 3
PRE 14A 2015-08-06 August 6, 2015 PRE 14A
4 2015-07-29 July 29, 2015 4
4 2015-07-24 July 23, 2015 4
8-K 2015-07-17 July 14, 2015 8-K
8-K/A 2015-07-08 June 30, 2015 8-K/A, Exhibits 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7
8-K 2015-07-07 June 30, 2015 8-K, Exhibit 99.1
4 2015-06-04 June 4, 2015 4
4 2015-05-29 May 28, 2015 4
4 2015-05-27 May 27, 2015 4
4 2015-05-26 May 26, 2015 4
10-Q 2015-05-18 March 31, 2015 10-Q, Exhibits 31.1, 31.2, 32
8-K 2015-04-10 April 06, 2015 8-K, Exhibit 99.1
10-K 2015-03-31 December 31, 2014 10-K, Exhibits 10.2.3, 10.2.4, 10.23.1, 10.26, 10.27, 10.29, 23.2, 31.1, 31.2, 32
8-K 2015-03-31 March 31, 2015 8-K, Exhibits 99.1, 99.2
5 2015-02-17 December 31, 2014 5
5 2015-02-17 December 31, 2014 5
5 2015-02-17 December 31, 2014 5
8-K 2015-01-20 January 12, 2015 8-K, Exhibit 10.1, 99.1
8-K 2015-01-06 December 29, 2014 8-K, Exhibit 99.1
8-K 2014-11-26 November 21, 2014 8-K
10-Q 2014-11-14 September 30, 2014 10-Q
8-K 2014-10-24 October 24, 2014 8-K, Exhibit 2.1, Exhibit 99.1, Exhibit 99.2
8-K 2014-09-19 September 19, 2014 8-K
8-K 2014-09-10 September 10, 2014 8-K
10-Q 2014-08-14 June 30, 2014 10-Q
10-Q 2014-05-15 March 31, 2014 10-Q
10-K/A 2014-04-15 December 31, 2013 10-K/A, Exhibits 10.1.10, 10.1.11, 10.3.5, 10.3.6, 10.11.5, 10.11.6, 10.38, 10.39, 10.40, 10.41, 10.42, 10.42.1, 10.42.2, 14.1.1, 23.2, 31.1, 31.2, 32, XBRL zip file
10-K 2014-04-15 December 31, 2013 10-K, Exhibits 10.1.10, 10.1.11, 10.3.5, 10.3.6, 10.11.5, 10.11.6, 10.38, 10.39, 10.40, 10.41, 10.42, 10.42(1), 10.42(2), 14.1.1, 23.2, 31.1, 31.2, 32
8-K 2014-03-31 March 31, 2014 8-K, Exhibit 99.1
NT 10-K 2014-03-31 March 31, 2014 NT 10-K
8-K 2014-03-21 March 21, 2014 8-K, Exhibit 99.1
8-K 2014-03-10 March 10, 2014 8-K, Exhibit 99.1
8-K 2014-03-03 March 3, 2014 8-K, Exhibit 99.1
SC 13G 2014-02-18 February 13, 2014 SC 13G
8-K 2014-01-29 January 23, 2014 8-K EX 99.1
8-K 2014-01-02 December 26, 2013 8-K EX 99.1
8-K 2013-12-19 December 19, 2013 8-K

10-Q

2013-11-14

September 30, 2013

10-Q

10-Q

2013-08-13

June 30, 2013

10-Q

8-K 2013-08-06 August 2, 2013 8-K
8-K 2013-08-05 August 1, 2013 8-K

8-K

2013-06-06

June 5, 2013

8-K

10-Q 2013-05-15 March 31, 2013 10-Q

10-K/A

2013-04-02

December 31, 2012

10-K/A, Exhibits 10.1(8), 10.1(9), 10.4(4), 10.5(4), 10.11(2), 10.11(3), 10.11(4), 10.15(2), 10.15(3), 10.19, 10.22(1), 10.36, 10.37, 31.1, 31.2, 32

10-K

2013-04-02

December 31, 2012

10-K

NT 10-K

2013-04-01

December 31, 2012

NT 10-K

8-K

2013-03-26

March 26, 2013

8K  EX-99.1 EX-10.1

8-K

2013-01-03

December 31, 2012

8-K

8-K

2012-11-15

November 15, 2012

8-KExhibit 99.1

10-Q

2012-11-14

September 30, 2012

10-Q, Exhibits 31.1, 31.2, 32

XBRL File (Zip Format)

8-K 2012-08-31 August 29, 2012 8-K
8-K 2012-08-15 August 14, 2012 8-K, Exhibit 99
10-Q 2012-08-14 June 30, 2012 10-Q, Exhibits 31.1, 31.2, 32
8-K 2012-07-31 July 26, 2012 8-K
8-K 2012-07-13 July 9, 2012 8-K
8-K 2012-06-28 June 28, 2012 8-K
CT ORDER 2012-06-20 June 20, 2012 CT ORDER
8-K 2012-06-14 June 13, 2012 8-K, Exhibit 99.1
10-Q 2012-05-21 March 31, 2012 10-Q, Exhibits 31.1, 31.2, 32
NT 10-Q 2012-05-14 March 31, 2012 NT 10-Q
8-K 2012-05-04 May 3, 2012 8-K
8-K 2012-04-09 April 6, 2012 8-K, Exhibit 99.1
8-K 2012-04-02 March 30, 2012 8-K, Exhibit 99.1
8-K 2012-03-15 March 15, 2012 8-K, Exhibit 99.1

 

More SEC Filings

Contact Investor Relations



Please note: Investing in the stock market involves the risk of loss. Please also see our Privacy Policy.